BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Ophthalmic drug developers are unlocking the full potential of
  gene therapy. Crucial lessons learnt from both clinical successes and fa
 ilures\, coupled with recent improvements in development and delivery\, m
 eans that the space is poised to capitalize on the significant potential 
 of the eye as a target for genetic medicine approaches.\n\nJoin 100+ indu
 stry leaders at the 5th Gene Therapy for Ophthalmic Disorders Summit to u
 ncover cutting-edge gene therapy breakthroughs. Harness the latest develo
 pments in vector engineering to target retinal cells more effectively wit
 h higher transduction efficiency. Understand the crucial role of endpoint
  selection to clearly demonstrate product efficacy to the FDA AND EMA. Un
 derstand the risk-benefit profiles of different ocular administration rou
 tes including intravitreal\, subretinal\, and suprachoroidal delivery to 
 choose the best option for your specific indication. Learn from successfu
 l clinical trials as well as where trials have fallen short of expectatio
 ns to take forward crucial lessons learnt on progressing a gene therapy r
 apidly through the clinic without compromising on safety.\n\n&nbsp\;\n\nT
 ime: 8:00 AM - 5:00 PM\n
DTEND:20240912T170000
DTSTAMP:20260514T153515Z
DTSTART:20240910T080000
LOCATION:Wyndham Boston Beacon Hill\, 5\, Blossom Street\, Boston\, Massac
 husetts\, 02114\,
SEQUENCE:0
SUMMARY:Ophthalmic drug developers are unlocking the full potential of gen
 e therapy. Crucial lessons learnt from both clinical successes and failur
 es\, coup...
UID:9aaf40e1-a99f-4c3f-8b54-5822d6dfdb75
END:VEVENT
END:VCALENDAR